文献速递心力衰竭与心肌病心律失常

射血分数降低心衰患者心房颤动类型与结局

Type of Atrial Fibrillation and Outcomes in Patients With Heart Failure and Reduced Ejection Fraction.
PubMed 文献 · J Am Coll Cardiol · 2017-01-01

本研究分析PARADIGM-HF和ATMOSPHERE两项试验中15,415例射血分数降低心衰患者,探讨心房颤动类型与结局的关系。结果显示,阵发性房颤患者主要复合终点、心衰住院和卒中风险高于无房颤者,而持续/永久性房颤风险未升高;新发房颤与所有不良结局风险最高相关。

要点

  • 阵发性房颤增加心衰住院和卒中风险,持续/永久性房颤风险未显著升高。
  • 新发房颤患者主要终点、心衰住院、卒中和全因死亡风险最高。
  • 阵发性和新发房颤患者抗凝药使用率较低,需重视抗凝治疗。

核心结论

  • 在射血分数降低心衰合并房颤病史的患者中,阵发性房颤较持续/永久性房颤有更高的心衰住院和卒中风险,新发房颤与所有不良结局风险增加相关。

研究设计与样本

  • 研究分析PARADIGM-HF和ATMOSPHERE两项试验中15,415例射血分数降低心衰患者,使用多变量Cox回归模型估计风险比。

主要发现

  • 5,481例(35.6%)有房颤病史,其中1,645例(30.0%)为阵发性房颤。
  • 与无房颤者相比,阵发性房颤患者主要复合终点风险HR 1.20(95%CI 1.09-1.32,p<0.001),心衰住院HR 1.34(95%CI 1.19-1.51,p<0.001),卒中HR 1.34(95%CI 1.02-1.76,p=0.037)。
  • 持续/永久性房颤患者上述风险未升高,两种房颤类型均与死亡率升高无关。
  • 新发房颤患者主要终点HR 2.21(95%CI 1.80-2.71),心衰住院HR 2.11(95%CI 1.58-2.81),卒中HR 2.20(95%CI 1.25-3.88),全因死亡HR 2.26(95%CI 1.86-2.74),所有p<0.001。
  • 阵发性房颤(53%)和新发房颤(16%)患者抗凝药使用率低于持续/永久性房颤(71%)。

临床怎么用

  • 对射血分数降低心衰合并阵发性或新发房颤患者,应评估抗凝治疗必要性,因其心衰住院和卒中风险较高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Atrial fibrillation (AF) is common in heart failure (HF), but the outcome by type of AF is largely unknown. OBJECTIVES: This study investigated outcomes related to type of AF (paroxysmal, persistent or permanent, or new onset) in 2 recent large trials in patients with HF with reduced ejection fraction. METHODS: The study analyzed patients in the PARADIGM-HF (Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure) and ATMOSPHERE (Aliskiren Trial to Minimize Outcomes in Patients with Heart Failure) trials. Multivariable Cox regression models were used to estimate hazard ratios (HRs) for outcomes related to AF type. RESULTS: Of 15,415 patients, 5,481 (35.6%) had a history of AF at randomization, and of these, 1,645 (30.0%) had paroxysmal AF. Compared with patients without AF, patients with paroxysmal AF at randomization had a higher risk of the primary composite endpoint of cardiovascular death or HF hospitalization (HR: 1.20; 95% confidence interval [CI]: 1.09 to 1.32; p < 0.001), HF hospitalization (HR: 1.34; 95% CI: 1.19 to 1.51; p < 0.001), and stroke (HR: 1.34; 95% CI: 1.02 to 1.76; p = 0.037), whereas the corresponding risks in patients with persistent or permanent AF were not elevated. Neither type of AF was associated with higher mortality. New onset AF was associated with the greatest risk of adverse outcomes: primary endpoint (HR: 2.21; 95% CI: 1.80 to 2.71), HF hospitalization (HR: 2.11; 95% CI: 1.58 to 2.81), stroke (HR: 2.20; 95% CI: 1.25 to 3.88), and all-cause mortality (HR: 2.26; 95% CI: 1.86 to 2.74), all p values < 0.001, compared with patients without AF. Anticoagulants were used less often in patients with paroxysmal (53%) and new onset (16%) AF than in patients with persistent or permanent AF (71%). CONCLUSIONS: Among HF patients with a history of AF, those with paroxysmal AF were at greater risk of HF hospitalization and stroke than were patients with persistent or permanent AF, underlining the importance of anticoagulant therapy. New onset AF was associated with increased risk of all outcomes. (Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure [PARADIGM-HF]; NCT01035255) (Aliskiren Trial to Minimize Outcomes in Patients with Heart Failure [ATMOSPHERE]; NCT00853658).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Mogensen UM, Jhund PS, Abraham WT, et al. Type of Atrial Fibrillation and Outcomes in Patients With Heart Failure and Reduced Ejection Fraction. J Am Coll Cardiol. 2017. PMID: 29145948. doi:10.1016/j.jacc.2017.09.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。